[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. - Wikidata - wikimedia - TriplyDB

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

http://www.wikidata.org/entity/Q53527477

about

Update on positron emission tomography for imaging of prostate cancer Imaging on nodal staging of prostate cancer.Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Cancer biomarker discovery: the entropic hallmark.Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.GCPII imaging and cancer.Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey.Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds.Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.The next generation of positron emission tomography radiopharmaceuticals in oncology.PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging Functional imaging for prostate cancer: therapeutic implications.Imaging techniques for prostate cancer: implications for focal therapy Imaging localized prostate cancer: current approaches and new developments.Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.New horizons in prostate cancer imaging.Novel tracers and their development for the imaging of metastatic prostate cancer.Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.Multi-modality organ-based approach to expected imaging findings, complications and recurrent tumour in the genitourinary tract after radiotherapy.68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.Radionuclide imaging of bone marrow disorders.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review.18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.Choline PET/CT for imaging prostate cancer: an update.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats.Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer.

P2860

Q27026828-4D693E06-2B7B-4A25-9A3E-B33AAC75C6D9 Q30244033-06F920F7-673A-4D3D-B93E-94BB8D042BE0 Q30354652-D3C18619-F3C5-4D0B-B6D3-5D4C5CD9A61E Q30496149-BE8F7FAA-4C9D-4261-9111-B1E459B4DCA5 Q33711641-009881E7-38C1-4C79-AA7A-9A14B2A9F22C Q33827632-0542ED1F-8EC4-4250-BADD-EBF63A76A2A5 Q33946322-A1509CB7-DF60-4A9B-B9AE-D49BEDCDC080 Q34040036-1CCA746A-1E3F-4908-B130-9D0FE241266B Q34228828-6C6B078E-8F09-4C2D-B3EF-51E1B8DAF5B8 Q34448206-7FFA0EF9-43E2-4A49-A6CC-4B27971937BD Q34465066-4499F1C8-89FC-45CE-88DE-E83BDC102B19 Q35155500-35F00E46-38ED-4101-A349-E9B2D4AB2B09 Q35525690-A146AA5E-46C5-4E8A-91F5-7B6990123D26 Q36085426-BE674067-AF79-4D75-9D7C-8E108F1FBEEA Q36103698-C3F8DDA4-A33F-4D0E-8492-E80ACEECDA12 Q36125199-10004805-F259-48D7-A00F-03C8D97EE9B3 Q36128629-FEBF612C-5F75-4BC0-BE91-F283DD6EC0EA Q36460818-0700FF68-2C61-48EA-A8E0-B8A3AFD1FBB2 Q36469177-F9CCE00C-AB0B-41C3-A60B-4E08EBC417C2 Q37086178-125B989E-D2D7-4319-8690-2E5C4EA11252 Q37242030-14B1374E-0504-45EB-A06A-89E248361A50 Q37321810-2AFA45D1-3F64-4FC6-872C-499EA9C2BBE9 Q37350456-F8A4AFAF-702E-4B82-8267-7C30971071DF Q37628932-FCB6E07F-1FB2-49E4-9AF8-7A577A153435 Q37707083-7B73D5BA-EEEE-4BE4-82EC-6EFEF561D711 Q37772107-F578F25B-C29F-4B25-BD68-5A88570217B3 Q37918311-30E2E3A1-EEA3-45D7-BA96-2266E9638572 Q37973351-7EE9E16E-33DC-4720-9658-FDDB54883F34 Q38098441-EE2CE164-909E-4C8F-A2AF-EB99127619A4 Q38103180-19E9C609-9916-47BA-95ED-338148ED8C19 Q38190115-3F5EA0B7-FC1F-43ED-8781-FEA819AB6212 Q38239699-06962EC2-DBB6-492A-A63C-E09129E80806 Q38479113-CDC7F8D4-1E8D-4653-90B4-9BF226D26FAE Q38532173-E85192C0-B8BC-4E32-9F03-984F4405F771 Q38920663-D78F9A4E-DC6D-4600-92FE-8581014B2AE9 Q38939387-7141E38B-F554-4B65-8F1C-63E9A8C33C61 Q39141778-F4C8DD2D-23B0-4CA4-B42C-8FA79E0B5343 Q39242140-3569161F-C6E8-42BE-9FBB-40097057386E Q39439595-619654E4-AC08-4138-A460-AE153DE54646 Q41094016-62D0E9CB-EAF7-4263-BD6E-B8127005E552

P2860

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

http://www.wikidata.org/entity/Q53527477

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@en

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@nl

type

label

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@en

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@nl

prefLabel

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@en

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@nl

P1433

Q53527477-47B51AF9-B12C-4B2E-A45B-CD02736DD227

P1476

Q53527477-69B107C8-CDA2-411E-92F3-C75728BE4B1C

P2093

Q53527477-22B60864-777C-4699-858D-2A4F2B18E1D3

Q53527477-35F32A1A-A6C8-4580-ACF4-CFE27099103C

Q53527477-767C2E00-1BA3-4B37-8139-CA10B1B7F290

Q53527477-8028515D-6C3D-48A8-AA21-25E157CE03AA

Q53527477-83FEED0F-A0EA-4C8E-9580-C9DD3AFC730D

Q53527477-92F28AA0-F755-44FB-8979-496905046757

Q53527477-B88FA39D-D2BB-4BD5-9454-D63633FBAE36

Q53527477-CF03FE48-CD57-4B1B-B731-F7AD8F7BC7B0

Q53527477-D34047AD-ABE9-4441-AE1C-7681203A61AD

P2888

Q53527477-08E6315E-281C-4BC1-9835-1706A5781C7B

P304

Q53527477-0B2280D9-23B0-4C8C-82C6-400B54E176D9

P31

Q53527477-C6ACB0A8-94B3-4169-B1F0-8E43A22381C3

P356

Q53527477-79ACC190-CFB4-44D3-868C-C69BB70E27BB

P433

Q53527477-2BA15CD0-0F2A-44AF-9B0F-7474F3BDC443

P478

Q53527477-D59FB618-8D4A-42C7-AFEA-3BBF3D78145D

P577

Q53527477-E121DDE6-64A2-4C74-B602-15030124E1CC

P698

Q53527477-54CED16D-2CBF-4D86-AB12-06575CF4826C

P921

Q53527477-F3DC5813-283C-448B-97BC-FCF48234F0E2

P356

S00259-006-0150-2

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

[18F]fluorocholine PET/CT imag ...... e in 100 consecutive patients.

@en

P2093

Annalisa Drigo

http://www.w3.org/2001/XMLSchema#string

Antonio Garbeglio

http://www.w3.org/2001/XMLSchema#string

Eugenio Borsatti

http://www.w3.org/2001/XMLSchema#string

Marino Cimitan

http://www.w3.org/2001/XMLSchema#string

Mauro G Trovò

http://www.w3.org/2001/XMLSchema#string

Roberto Bortolus

http://www.w3.org/2001/XMLSchema#string

Sandro Morassut

http://www.w3.org/2001/XMLSchema#string

Tanja Baresic

http://www.w3.org/2001/XMLSchema#string

Vincenzo Canzonieri

http://www.w3.org/2001/XMLSchema#string

P2888

s00259-006-0150-2

P304

1387-1398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-006-0150-2

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16865395

http://www.w3.org/2001/XMLSchema#string

P921